"Dr. Chari On The Subgroup Analysis Of MMY1001 In Multiple Myeloma"
Ajai Chari, MD, associate professor of medicine, hematology and medical oncology, and director of clinical research in multiple myeloma program at the Icahn School of Medicine at Mount Sinai, discusses the subgroup analysis of MMY1001 in multiple myeloma. MMY1001 examined the use of daratumumab in combination with carfilzomib and dexamethasone. The subgroup analysis looked specifically at lenalidomide refractory patients with relapsed multiple myeloma. The rationale came from the fact that there is an increasing use of multiple myeloma. The rationale came from the fact that there is an increasing use of lenalidomide maintenance after induction therapy and transplant, said Dr. Chari.
- Ajai Chari, MD, Associate Professor, Medicine, Hematology, Medical Oncology, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Icahn School of Medicine at Mount Sinai